NASDAQ:CRME - Cardiome Pharma Stock Price, News, & Analysis Notice: This company has been marked as potentially delisted and may not be actively trading. Sign in or create an account to add this stock to your watchlist. Get Started Previous Close$2.33Today's Range$2.30 - $2.4552-Week Range$1.29 - $4.84Volume90,444 shsAverage Volume135,322 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsChartEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Cardiome Pharma Corp., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of patients suffering from heart diseases. It offers BRINAVESS (vernakalant (IV)) for the conversion of recent onset atrial fibrillation to sinus rhythm in adults; and AGGRASTAT, a reversible GP IIb/IIIa inhibitor for use in acute coronary syndrome patients. The company also provides ESMOCARD and ESMOCARD LYO short-acting beta-blockers used to control rapid heart rate; XYDALBA, a semi-synthetic lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections; and TREVYENT for the treatment of pulmonary arterial hypertension. It has operations in Canada, the United States, Europe, and internationally. The company was formerly known as Nortran Pharmaceuticals Inc. and changed its name to Cardiome Pharma Corp. in June 2001. Cardiome Pharma Corp. was founded in 1986 and is headquartered in Vancouver, Canada. Receive CRME News and Ratings via Email Sign-up to receive the latest news and ratings for CRME and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CRME Previous Symbol CUSIPN/A CIK1036141 Webhttp://www.cardiome.com/ Phone604-677-6905Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding SharesN/AMarket CapN/A Next Earnings DateN/A OptionableOptionable Cardiome Pharma (NASDAQ:CRME) Frequently Asked Questions What is Cardiome Pharma's stock symbol? Cardiome Pharma trades on the NASDAQ under the ticker symbol "CRME." How were Cardiome Pharma's earnings last quarter? Cardiome Pharma Co. (NASDAQ:CRME) posted its quarterly earnings data on Tuesday, May, 15th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.22) by $0.02. The biopharmaceutical company had revenue of $6.54 million for the quarter, compared to the consensus estimate of $7.34 million. View Cardiome Pharma's Earnings History. Has Cardiome Pharma been receiving favorable news coverage? Media stories about CRME stock have trended neutral recently, according to InfoTrie Sentiment. The research group ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Cardiome Pharma earned a media sentiment score of 0.3 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the near term. Who are some of Cardiome Pharma's key competitors? Some companies that are related to Cardiome Pharma include Advanced Accelerator Application (AAAP), Affymax (AFFY), American Oriental Bioengineering (AOBI), Aralez Pharmaceuticals (ARLZ), ARMO Biosciences (ARMO), Bohai Pharmaceuticals Group (BOPH), Concordia International (CXRXD), Concordia International (CXRX), Depomed (DEPO), Egalet (EGLT), Eleven Biotherapeutics (EBIO), Epirus Biopharmaceuticals (EPRSQ), ERBA Diagnostics (ERBA), FutureWorld (FWDG) and GlobeImmune (GBIM). What other stocks do shareholders of Cardiome Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cardiome Pharma investors own include Energy Transfer LP Unit (ET), CBL & Associates Properties (CBL), SandRidge Permian Trust (PER), Cornerstone Strategic Value Fund (CLM), Cornerstone Total Return Fund (CRF), SunCoke Energy Partners (SXCP), Martin Midstream Partners (MMLP), Navios Maritime Midstream Partners (NAP), Government Properties Income Trust (GOV) and Arlington Asset Investment (AI). Who are Cardiome Pharma's key executives? Cardiome Pharma's management team includes the folowing people: Dr. William L. Hunter, Pres, CEO & Director (Age 55)Ms. Sheila M. Grant MBA, Chief Operating OfficerMr. David D. McMasters, Gen. Counsel (Age 59)Mr. Hugues Sachot, Chief Commercial OfficerMr. Justin A. Renz, Chief Financial Officer (Age 46) What is Cardiome Pharma's official website? The official website for Cardiome Pharma is http://www.cardiome.com/. How can I contact Cardiome Pharma? Cardiome Pharma's mailing address is 1441 Creekside Drive 6th Floor, Vancouver A1, V6J 4S7. The biopharmaceutical company can be reached via phone at 604-677-6905 or via email at [email protected] MarketBeat Community Rating for Cardiome Pharma (NASDAQ CRME)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 255 (Vote Outperform)Underperform Votes: 237 (Vote Underperform)Total Votes: 492MarketBeat's community ratings are surveys of what our community members think about Cardiome Pharma and other stocks. Vote "Outperform" if you believe CRME will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRME will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/24/2019 by MarketBeat.com StaffFeatured Article: Why is momentum important to successful trading? Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.